---
document_datetime: 2023-09-21 18:04:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/symtuza-epar-all-authorised-presentations_en.pdf
document_name: symtuza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7340955
conversion_datetime: 2025-12-19 02:24:27.406266
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number        | (Invented) name   | Strength                         | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size           |
|------------------|-------------------|----------------------------------|-----------------------|---------------------------|-----------------------|---------------------|
| EU/1/17/1225/001 | Symtuza           | 800 mg / 150 mg / 200 mg / 10 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets          |
| EU/1/17/1225/002 | Symtuza           | 800 mg / 150 mg / 200 mg / 10 mg | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 90 (3 x 30) tablets |